source
- Revolution Medicines' Rasonque shows 42% response and 16-month survival in NSCLC subgroupData from a subgroup of an earlier trial, described by Truist Securities as the most relevant to Revolution Medicines' ongoing Phase 3 study, reported a 42% overall response rate and a median overa…
- FDA alerts hospitals to purge cassette fault in Abiomed Impella controllersThe FDA issued an Early Alert after identifying a problem with the purge cassette recognition in Abiomed’s Automated Impella Controllers, which could cause prolonged delays in mechanical circulator…